Lumavita

Lumavita is a specialty biopharmaceutical company located in Basel, Switzerland, and dedicated to the development of anti-infective drugs for women’s health. Lumavita’s portfolio consists of LMV-601, a first-in-class anti-viral compound (treatment of Human Papilloma Virus infections leading to cervix cancer) currently in Phase I, and LMV-602 (pentamycin), foreseen to cure vaginitis caused by both candida and trichomonas.


Recent News

August 27, 2009
Lumavita AG announces Marketing Authorisation for Pentamycin in Switzerland

 
June 18, 2009
Lumavita AG announces new funding

 
March 24, 2009
Lumavita AG announces receipt of Preliminary Approval for Marketing Authorisation of pentamycin in Switzerland for the treatment of

 


Company Info
 
Country: Switzerland
Industry:    LS
Sector: biotechnology
Status: Unrealized
Vehicle: Endeavour II LP


Company website
 www.lumavita.com


Endeavour Vision Team
 
Olivier Valdenaire
Sven Lingjaerde
© Endeavour Vision SA 2006-2013 Terms & Conditions